Related Experiment Videos
[Comprehensive evaluation of cefotetan in pediatrics]
The Japanese Journal of Antibiotics
|June 1, 1983
Summary
Cefotetan (CTT), a cephamycin antibiotic, shows promising pharmacokinetic and clinical efficacy in pediatric patients. This new antibiotic is effective in treating various pediatric infections with minimal side effects.
Area of Science:
- Pharmacology
- Infectious Diseases
- Pediatrics
Background:
- Cefotetan (CTT) is a novel cephamycin antibiotic.
- Pediatric infections require effective and safe treatment options.
Purpose of the Study:
- To evaluate the pharmacokinetics and clinical efficacy of cefotetan (CTT) in pediatric patients.
- To assess the safety profile of CTT in a pediatric population.
Main Methods:
- Pharmacokinetic study in 20 pediatric patients with normal renal function.
- Intravenous administration of CTT at 20 mg/kg.
- Clinical efficacy evaluated in 285 pediatric patients across various infections.
Main Results:
- Mean CTT half-life was 2.61 hours with 68.1% urinary excretion within 8 hours.
- High clinical response rates observed: 83.3% for sepsis, 89.3% for pneumonia, 96.2% for bronchitis/tonsillitis, and 92.5% for UTIs.
- Minimal side effects (2.6% diarrhea, 0.3% rash) and transient laboratory abnormalities were noted.
Conclusions:
- Cefotetan (CTT) demonstrates favorable pharmacokinetics and significant clinical effectiveness in treating pediatric infections.
- CTT is a safe and useful therapeutic option for various pediatric infectious diseases.